Age-related Macular Degeneration Market - By Product, By Disease Type, By Age Group, By Distribution Channel - & Global Forecast, 2024 to 2032

Age-related Macular Degeneration Market Size

The global age-related macular degeneration market size was valued at USD 10.4 billion in 2023 and is estimated to grow at 9.8% CAGR from 2024 to 2032. Age-related macular degeneration (AMD) is a disease that occurs in the eye and can affect central vision. It occurs due to gradual aging and damage to the macula, the part of the eye that sees directly and sharply. The macula is in the retina, the eye's sensitive tissue at the eye's rear end.
 

The AMD market is expected to grow due to new products, new innovations, and increasing AMD incidence. The Population Reference Bureau estimates that by 2050, those aged sixty-five and above will swell to 82 million from 58 million, increasing by 47% within the span. This forecast indicates that there will rapidly be a boom in aging in the U.S. population.
 

Furthermore, older people are at risk of various chronic problems like diabetes and hypertension, which increases the chances of AMD. The National Council on Aging states that almost 95% of older people have one chronic issue and 80% have two or more issues. The chances of these conditions appearing are increasing; therefore, it is urgent to find smart solutions to their management and AMD treatment. This underscores the need to develop holistic healthcare solutions targeting older people with chronic problems while reducing the risk of AMD.
 

Moreover, AMD research and development is expanding the treatment options for patients. For instance, the rise in innovations that include new ophthalmic drugs like anti-VEGF medicines, corticosteroids, and gene therapies valued at USD 31 billion by 2023. In addition, according to the American Academy of Ophthalmology, Anti-VEGF treatment improves vision in approximately one-third of the recipients, while some 90% have their vision stabilized.
 

Therefore, enhanced treatment outcomes resulting from these advancements are likely to stimulate market growth. Thus, as new research techniques develop, these therapies will improve the quality of life for AMD patients and help slow the disease's progress.
 

Age-related Macular Degeneration Market Trends

• The increasing knowledge of age-related macular degeneration (AMD) among both healthcare practitioners and the general population has fostered increased screenings and more timely detections. Such campaigns that enhance public health awareness alongside educational materials have motivated the population to adopt pre-emptive measures, thereby increasing the supply for AMD treatments.
   

• As per the WHO report, 8.7% of global blindness in people was due to AMD, which affected over 196 million people. This increasing prevalence of AMD coupled with rising awareness and early detection to reduce the global AMD burden, increases the adoption of treatment products, that contribute to market growth.
   

• These developments are intensifying AMD as a subject for government-driven programs and health policies to improve eye care and increase access to ophthalmic services.
   

• The financial increase of research and advocacy undertakings is beneficial not only in developing new treatment modalities but also in promoting eye examinations. Such a pattern highlights the commitment of the public health sectors to provide solutions to the problems associated with AMD and to seek higher levels of treatment.
   

• Currently, pharmaceutical companies and healthcare organizations are initiating patient assistance and support programs that make treatment easier to access. These pilot programs aid patients with insurance and other financial challenges to remain compliant with the prescribed treatment.
   

• These support groups are essential to those patients suffering from AMD as they lessen the financial burden which makes it easier for patients to access and adhere to treatment. This alliance potentially decreases the impact of vision loss in the aging population.
   

Age-related Macular Degeneration Market Analysis

Based on product, the market is segmented into Eylea, Lucentis, Beovu, Vabysmo, Syfovre, Avastin, and other products. In 2023, Eylea led the market, generating a substantial revenue of USD 4.4 billion.
 

• Eylea has been a global leader in anti-vein endothelial growth factor therapies for wet AMD since being granted FDA approval in 2011. This market continuity and expansion has earned tremendous confidence with providers, patients, and consumers which is why Eylea continues to reign even with recent therapy developments.
   
• Eylea has undoubtedly established itself as the primary treatment choice for ophthalmologists and patients owing to its thorough record of accomplishment of safety and effective clinical outcomes.
   
• The European Medicines Agency states that Eylea is on par with ranibizumab in maintaining visual acuity in patients suffering from wet AMD. Such Eylea's consistent performance in the clinical setting has fortified its position in treatment protocols for AMD.
   
• Eylea customizes treatment frequency to individual needs and enhances patient adherence which is a fundamental aspect in the treatment of chronic disorders such as AMD. These features alongside approvals for monthly and bi-monthly applying enables Eylea to offer patients optimized customizability.
   
• In addition, with an ever-growing population, the chances of encountering old age-related sickness also increase. Such factors accentuate the importance of Eylea's customizability to treatment on a global scale.

Based on disease type, the age-related macular degeneration market is bifurcated into wet AMD and dry AMD. The wet AMD segment dominated the market with the largest revenue of USD 8.5 billion in 2023.
 

• Wet AMD is responsible for a significant amount of eyesight loss globally amongst old, aged individuals. It is the result of abnormal blood vessel growth beneath the retina permitting the leaking of fluid and subsequent attrition of central vision. Most current therapies are aimed at antagonizing the vascular endothelial growth factor (VEGF) to control blood vessel growth and limit fluid leakage.
   
• As life expectancy increases, more people could risk the development of diseases associated with aging eyes. The challenge of devising effective vision-preserving treatments is therefore an increasing global issue. The World Health Organization predicts that by 2050, the global population above the age of 60 years will reach 2.1 billion, meaning that there would be a staggering increase in AMD incidences.
   
• Many older patients with wet AMD experience problems with the excessive frequency of regular injections required to manage the disease – often monthly or bi-monthly. Innovations like Vabysmo, which correlate with the need for less regular administration of injections, extend the time between prescribed excursions.
   
• Such advancements improve the quality of life and most importantly, adherence efforts for those suffering from poor mobility or worse access.
   
• Thus, it can be concluded that within the dynamics set forth, the wet AMD segment has significant growth expectation over the upcoming years.
   

Based on age group, the age-related macular degeneration market is segmented into 50–64 years, 65–74 years, and 75 and above. The 75 and above segment is projected to reach USD 12.3 billion by 2032.
 

• For patients 75 years and above, the primary treatments for age-related macular degeneration (AMD) include the use of anti-VEGF agents, laser therapy, photodynamic therapy, and oral supplements. Lucentis, Eylea, and Avastin are usually prescribed because they help dampen vision loss in patients with wet AMD.
   
• This class of medications works by restricting the abnormal formation and leaking of blood vessels in the retina. At the closer end of the spectrum, for the more slowly progressing dry AMD, doctors may recommend lifestyle changes and supplements rich in antioxidants, zinc, and copper to help slow down the progression of this disease.
   
• Drastic changes in life expectancy tend to increase the mortality demographic of 75 years and older due to the greatest prevalence of AMD. The UN reports suggest population growth aged 80+ is likely to climb from 143 million in 2019 to 426 million by 2050. Due to this, there is going to be an increase in AMD cases and fortifying the need for treatment.
   
• These factors will allow the segmented market to boost growth in the coming years.
   

Based on distribution channel, the age-related macular degeneration market is segmented into hospital pharmacies, specialty pharmacies, and e-commerce. In 2023, the hospital pharmacies segment was valued at USD 5.4 billion.
 

• Hospitals have the resources to create programs that provide patient support and AMD treatment strategies; hence hospital pharmacies have the upper hand.
   
• AMD treatment has financial limitations and affordable hospital-linked insurance schemes are common. Most clinics will not have them, and coupled with AMD treatments, solo clinics would benefit immensely from these schemes.
   
• AMD is a major issue for U.S. elderly, and these patients would benefit from general hospital pharmacies more than other types. Patients usually come to these hospitals for many social services, and so need support like these, as it makes these patients much more efficient in terms of mobility, so it is especially useful for patients with limited mobility.

In 2023, the U.S. age-related macular degeneration market was valued at USD 4.2 billion, with projections indicating a growth at a CAGR of 9.9% over the forecast period.
 

• The older populace is increasing, and that is one sector of society that will always be affected by AMD. The U.S. Census Bureau estimates the quantity of 65-plus citizens in America to be 95 million by the year 2060, an increase from 52 million in 2018.
   
• The rise in the global demographic population will drive the demand for age-related macular degeneration, given that it escalates with age. As the elderly population grows, so will the cases of AMD, underscoring the need for more advanced and accessible treatment options.
   
• There is tremendous development and advancement of AMD treatments in the U.S. where biopharmaceutical R&D is at the best level. Major pharmaceutical companies and research institutions in the U.S. are at the forefront, developing advanced treatments for AMD, including gene therapies, extended-release formulations, and combination therapies. This vibrant research landscape solidifies the U.S.'s position as a pioneer for novel therapy for AMD and can improve the lives of many patients worldwide.
   

From 2024 to 2032, the age-related macular degeneration market in the UK is poised for significant growth.
 

• Patients in the UK gain extensive coverage with the NHS for AMD treatments like anti-vascular endothelial growth factor (anti-VEGF) injections such as Lucentis and Eylea. Due to NHS reimbursements, patients can use this therapy at an affordable rate, while spending a negligibly low amount from their own pockets. This high affordability propels the AMD treatment market growth within the UK.
   
• The UK has launched a few public health and screening programs aimed at early detection of AMD for risk groups.
   
• With such measures put in place, a greater number of patients will be able to benefit from AMD treatments, since they will be diagnosed earlier, as well as be able to receive treatment in a much timelier fashion, which helps not just only put a stop to the disease's progression but also reduce the severity of symptoms the patients experience.
   
• Public eye healthcare measures like such will ensure that the focus on AMD treatment in the future remains strong. Most Americans over the age of sixty are likely to have AMD; for instance, the NHS provides them with free eye examinations on a bi-annual basis and gives them AMD detection spectacles.
   

Between 2024 and 2032, Japan age-related macular degeneration market is set for notable growth.
 

• The latest data from WHO informs that as of 2023, women in Japan live for an average of 87.14 years while men live for 81.09, making Japan one of the top-ranked countries in the world regarding life expectancy.
   
• Citing the BBC for this piece of information, the gradual increase in life expectancy has led to over 29.1% of Japanese citizens aged over sixty-five, resulting in an increased demand for services and treatment aimed at AMD, as older adults become more susceptible to ophthalmic disorders. This phenomenon will contribute to the increase in eye care provision in Japan.
   
• In addition to that, Japan's national healthcare system provides AMD treatment, including anti-VEGF therapies, under full coverage.
   
• Such inclusion in public health insurance not only enhances patients' access but also stimulates market development.
   

Saudi Arabia age-related macular degeneration market is set for significant growth from 2024 to 2032.

• The Saudi Arabia market is expected to undergo tremendous development between 2024 and 2032. In Saudi Arabia, chronic illnesses such as diabetes, hypertension, and obesity are quite common.
   
• According to the World Health Organization, the prevalence of diabetes in Saudi Arabia was reported to be 17.7% in the year 2021. These chronic illnesses increase the risk of age-related macular degeneration (AMD) eye diseases most relevant in older people.
   
• The International Diabetes Federation states that diabetic people are more susceptible to AMD compared to people who do not have this illness. With the increase in the prevalence of chronic diseases, there is a high requirement for AMD treatment and prevention strategies which calls for adequate eye care services in the country.
   
• The Saudi government is investing a lot of resources to accompany its Vision 2030 initiative in healthcare infrastructure, and this along with other investments seeks to improve access to sophisticated healthcare services and treatments. New investments in hospitals, clinics, and diagnostic facilities are expected to improve access to treatment for AMD among the Saudi population.
   

Age-related Macular Degeneration Market Share

Competitors in the market span a wide range, including both major international corporations and smaller or medium-sized firms fighting for a share of the market. One strategy that stands out in this industry is the regular launching of new technology-based products. By virtue of their scale, some companies lead these developments because of the impact they have on the market and the consequent R&D expenditure.
 

Strategic moves like these, together with the formation of international business joint ventures, mergers, and acquisitions, are critical for strengthening positions in existing markets and penetrating new markets with changing institutional frameworks. At the same time, smaller suppliers target specific niches to compete with the larger established ones.
 

Age-related Macular Degeneration Market Companies

Some of the eminent market participants operating in the age-related macular degeneration industry include:

• Adverum Biotechnologies
• Alkeus Pharmaceuticals
• Amgen
• Astellas Pharma
• Bausch Health Companies
• Bayer AG
• Biogen
• Coherus BioSciences
• F. Hoffmann-La Roche
• Kodiak Sciences
• Novartis AG
• Pfizer
• Regeneron Pharmaceuticals
• Sandoz Group AG
• STADA Arzneimittel AG
   

USPs for the top market players:

• Comprehensive portfolio with advanced delivery systems
   
• Global market presence with strategic partnership and marketing
   
• Investment in gene therapies and novel biologics for AMD treatment
   

Age-related Macular Degeneration Market Industry News:

• In July 2024, Genentech, part of the Roche Group, reintroduced Susvimo (ranibizumab injection) 100 mg/mL via ocular implant for intravitreal use. This treatment targets individuals in the U.S. with wet, or neovascular AMD. The relaunch is poised to boost patient access to effective treatments and enhance adherence by reducing injection frequency.
   
• In September 2021, AbbVie and REGENXBIO Inc. forged a partnership to develop and commercialize RGX-314, a promising one-time gene therapy aimed at wet AMD, diabetic retinopathy (DR), and other chronic retinal ailments. As per the collaboration, AbbVie spearheads the clinical development and global commercialization of RGX-314, while REGENXBIO plays a role in U.S. commercialization efforts.
   

The age-related macular degeneration market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Eylea
• Lucentis
• Beovu
• Vabysmo
• Syfovre
• Avastin
• Other products

Market, By Disease Type

• Wet AMD
• Dry AMD

Market, By Age Group

• 50–64 years
• 65–74 years
• 75 and above

Market, By Distribution Channel

• Hospital pharmacies
• Specialty pharmacies
• E-commerce

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands 
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE